On November 4, 2021 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, reported that Maurice Zauderer, Ph.D., President and Chief Executive Officer, is scheduled to present virtually at the 12th Annual Jefferies London Healthcare Conference and invites investors to participate in virtual one-on-one meetings on Thursday and Friday, November 18th and 19th (Press release, Vaccinex, NOV 4, 2021, View Source [SID1234594566]). Please see Presentation details below:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
12th Annual Jefferies London Healthcare Conference
Date: November 18th to 19th, 2021
Time: Virtual presentation available Thursday, November 18 at 8:00am GMT/3:00am ET through Friday, November 19 at 5:00pm GMT / 12:00pm ET
Presenter: Maurice Zauderer, Ph.D., President and Chief Executive Officer
Webcast Link: View Source;group=TbkBHEif
Replay: The presentation and a replay of the webcast will be available on Vaccinex’s website shortly after the event at: View Source
Please contact your Jefferies representative or Vaccinex if you would like to participate in a virtual one-on-one meeting during the conference.
For more information about the Jefferies London Healthcare Conference, please refer to the Jefferies conference website. Vaccinex’s presentation will also be available on the Jefferies website for 30 days after the conference.